111 related articles for article (PubMed ID: 22706233)
1. Molecular mechanisms underlying statin effects on genes involved in the reverse cholesterol transport.
Cerda A; Hirata MH; Hirata RD
Drug Metabol Drug Interact; 2012 May; 27(2):101-11. PubMed ID: 22706233
[TBL] [Abstract][Full Text] [Related]
2. Pleiotropic effects of statins: evidence against benefits beyond LDL-cholesterol lowering.
Pedersen TR
Am J Cardiovasc Drugs; 2010; 10 Suppl 1():10-7. PubMed ID: 21391729
[TBL] [Abstract][Full Text] [Related]
3. Brothers in Arms: ABCA1- and ABCG1-Mediated Cholesterol Efflux as Promising Targets in Cardiovascular Disease Treatment.
Frambach SJCM; de Haas R; Smeitink JAM; Rongen GA; Russel FGM; Schirris TJJ
Pharmacol Rev; 2020 Jan; 72(1):152-190. PubMed ID: 31831519
[TBL] [Abstract][Full Text] [Related]
4. Cross-talk between exogenous statins and endogenous high-density lipoprotein in anti-inflammatory and anti-atherogenic actions.
Kimura T; Sato K; Tomura H; Okajima F
Endocr Metab Immune Disord Drug Targets; 2010 Mar; 10(1):8-15. PubMed ID: 20105136
[TBL] [Abstract][Full Text] [Related]
5. Effects of statin and lipoprotein metabolism in heart failure.
Miura S; Saku K
J Cardiol; 2010 May; 55(3):287-90. PubMed ID: 20350519
[TBL] [Abstract][Full Text] [Related]
6. The pharmacologic elegance of inhibiting cholesterol absorption and synthesis while providing a homeostatic balance.
Catapano AL
Fundam Clin Pharmacol; 2007 Nov; 21 Suppl 2():21-6. PubMed ID: 18001316
[TBL] [Abstract][Full Text] [Related]
7. [New treatment option for decreasing blood cholesterol level--clinical significance of inhibition of both, cholesterol absorption and synthesis].
Paragh G; Márk L; Czine Z
Orv Hetil; 2004 Apr; 145(15):805-11. PubMed ID: 15188635
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us?
Fabbri G; Maggioni AP
Adv Ther; 2009 May; 26(5):469-87. PubMed ID: 19444394
[TBL] [Abstract][Full Text] [Related]
9. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men.
Bennett S; Sager P; Lipka L; Melani L; Suresh R; Veltri E;
J Womens Health (Larchmt); 2004 Dec; 13(10):1101-7. PubMed ID: 15650343
[TBL] [Abstract][Full Text] [Related]
10. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
Hausenloy DJ; Yellon DM
Heart; 2008 Jun; 94(6):706-14. PubMed ID: 18480348
[TBL] [Abstract][Full Text] [Related]
11. [Mechanisms of statin nephroprotective actions].
Chmielewski M; Zdrojewski Z; Rutkowski B
Przegl Lek; 2002; 59(7):519-22. PubMed ID: 12516241
[TBL] [Abstract][Full Text] [Related]
12. Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy.
Pearson TA; Ballantyne CM; Veltri E; Shah A; Bird S; Lin J; Rosenberg E; Tershakovec AM
Am J Cardiol; 2009 Feb; 103(3):369-74. PubMed ID: 19166691
[TBL] [Abstract][Full Text] [Related]
13. Reverse cholesterol transport in type 2 diabetes mellitus.
Tan KC
Diabetes Obes Metab; 2009 Jun; 11(6):534-43. PubMed ID: 19175378
[TBL] [Abstract][Full Text] [Related]
14. Lifibrol as a model compound for a novel lipid-lowering mechanism of action.
Berthold HK; Sudhop T; von Bergmann K; Gouni-Berthold I
J Cardiovasc Pharmacol Ther; 2010 Dec; 15(4):364-72. PubMed ID: 20693157
[TBL] [Abstract][Full Text] [Related]
15. Perspectives of the non-statin hypolipidemic agents.
Rozman D; Monostory K
Pharmacol Ther; 2010 Jul; 127(1):19-40. PubMed ID: 20420853
[TBL] [Abstract][Full Text] [Related]
16. State of the art in cholesterol management: targeting multiple pathways.
Turley SD
Am J Manag Care; 2002 Feb; 8(2 Suppl):S29-32; discussion S45-7. PubMed ID: 11855699
[TBL] [Abstract][Full Text] [Related]
17. Hydroxypropylmethylcellulose lowers cholesterol in statin-treated men and women with primary hypercholesterolemia.
Maki KC; Carson ML; Miller MP; Anderson WH; Turowski M; Reeves MS; Kaden V; Dicklin MR
Eur J Clin Nutr; 2009 Aug; 63(8):1001-7. PubMed ID: 19209184
[TBL] [Abstract][Full Text] [Related]
18. Models for describing relations among the various statin drugs, low-density lipoprotein cholesterol lowering, pleiotropic effects, and cardiovascular risk.
Robinson JG
Am J Cardiol; 2008 Apr; 101(7):1009-15. PubMed ID: 18359323
[TBL] [Abstract][Full Text] [Related]
19. Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin.
Gazi IF; Daskalopoulou SS; Nair DR; Mikhailidis DP
Curr Med Res Opin; 2007 Sep; 23(9):2183-92. PubMed ID: 17692154
[TBL] [Abstract][Full Text] [Related]
20. Nicotinic acid and other therapies for raising high-density lipoprotein.
Carlson LA
Curr Opin Cardiol; 2006 Jul; 21(4):336-44. PubMed ID: 16755203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
